AI Score
Our AI model analyzes fundamental, technical, and statistical indicators
to predict the probability of a bullish trend over the next three months.
We regularly update and refine our models to deliver the most reliable forecasts
for you.
Bullish Probability | Sentiment | Score |
---|---|---|
+80% | Strong Buy | 10 |
+75% | Buy | 9 |
+70% | Buy | 8 |
+60% | Buy | 7 |
+50% | Hold | 6 |
+45% | Hold | 5 |
+40% | Hold | 4 |
+35% | Sell | 3 |
+30% | Sell | 2 |
+20% | Strong Sell | 1 |
Galera Therapeutics Statistics
Share Statistics
Galera Therapeutics has 54.39M shares outstanding. The number of shares has increased by 0% in one year.
Shares Outstanding | 54.39M |
Shares Change (YoY) | n/a |
Shares Change (QoQ) | 0% |
Owned by Institutions (%) | n/a |
Shares Floating | 39.94M |
Failed to Deliver (FTD) Shares | 2 |
FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 2.12M, so 3.9% of the outstanding shares have been sold short.
Short Interest | 2.12M |
Short % of Shares Out | 3.9% |
Short % of Float | 5.32% |
Short Ratio (days to cover) | 1.16 |
Valuation Ratios
The PE ratio is -0.11 and the forward PE ratio is -0.04.
PE Ratio | -0.11 |
Forward PE | -0.04 |
PS Ratio | 0 |
Forward PS | null |
PB Ratio | -0.05 |
P/FCF Ratio | -0.14 |
PEG Ratio | n/a |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Galera Therapeutics Inc..
EV / Earnings | n/a |
EV / Sales | n/a |
EV / EBITDA | n/a |
EV / EBIT | n/a |
EV / FCF | n/a |
Financial Position
The company has a current ratio of 4.36, with a Debt / Equity ratio of -0.01.
Current Ratio | 4.36 |
Quick Ratio | 4.36 |
Debt / Equity | -0.01 |
Total Debt / Capitalization | -0.96 |
Cash Flow / Debt | -35.88 |
Interest Coverage | 0 |
Financial Efficiency
Return on equity (ROE) is 0.45% and return on capital (ROIC) is 36.13%.
Return on Equity (ROE) | 0.45% |
Return on Assets (ROA) | -2.26% |
Return on Capital (ROIC) | 36.13% |
Revenue Per Employee | 0 |
Profits Per Employee | -8.44M |
Employee Count | 7 |
Asset Turnover | 0 |
Inventory Turnover | 0 |
Taxes
Income Tax | 0 |
Effective Tax Rate | 0 |
Stock Price Statistics
The stock price has increased by -76.16% in the last 52 weeks. The beta is 1.99, so Galera Therapeutics 's price volatility has been higher than the market average.
Beta | 1.99 |
52-Week Price Change | -76.16% |
50-Day Moving Average | 0.04 |
200-Day Moving Average | 0.1 |
Relative Strength Index (RSI) | 57.28 |
Average Volume (20 Days) | 241.07K |
Income Statement
Revenue | n/a |
Gross Profit | -259.00K |
Operating Income | -46.95M |
Net Income | -59.08M |
EBITDA | -46.69M |
EBIT | n/a |
Earnings Per Share (EPS) | -1.33 |
Balance Sheet
The company has 18.26M in cash and 1.25M in debt, giving a net cash position of 17.01M.
Cash & Cash Equivalents | 18.26M |
Total Debt | 1.25M |
Net Cash | 17.01M |
Retained Earnings | -437.41M |
Total Assets | 8.90M |
Working Capital | 7.99M |
Cash Flow
In the last 12 months, operating cash flow was -44.85M and capital expenditures -59.00K, giving a free cash flow of -44.91M.
Operating Cash Flow | -44.85M |
Capital Expenditures | -59.00K |
Free Cash Flow | -44.91M |
FCF Per Share | -1.01 |
Margins
Gross Margin | n/a |
Operating Margin | n/a |
Pretax Margin | n/a |
Profit Margin | n/a |
EBITDA Margin | n/a |
EBIT Margin | n/a |
FCF Margin | n/a |
Dividends & Yields
GRTX does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Payout Ratio | n/a |
Earnings Yield | -2660% |
FCF Yield | -1790.92% |
Analyst Forecast
Currently there are no analyst rating for GRTX.
Price Target | n/a |
Price Target Difference | n/a |
Analyst Consensus | n/a |
Analyst Count | n/a |
Scores
Altman Z-Score | -77.23 |
Piotroski F-Score | 3 |